Initiator Pharma A/S, a clinical-stage biotech company, today announced it will attend the BIO International Convention 2026, taking place on 22–25 June in San Diego, USA. Initiator Pharma’s CEO, Claus Olesen, will be available for meetings at the convention.
The BIO International Convention is the world’s largest partnering event for the global biotech industry, gathering more than 20,000 delegates annually from pharmaceutical companies, investors, and research organisations. The convention is a key meeting place for partnerships, licensing deals, and life sciences investments.
“BIO is a formidable arena for international business development in the biotech industry, and we enter this year’s convention in a stronger position within sexual health and neuropathic pain than ever before. The progress made in the vulvodynia study, the decision to fully commit to our lead asset pudafensine, and a strengthened IP position all contribute to a clearer and more compelling case,” says Claus Olesen, CEO of Initiator Pharma.
To book a meeting with Initiator Pharma during the convention, please contact ceo@initiatorpharma.com or use the BIO Partnering system.